Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902358 | 0.88 | SMN1; SMN2 (0.76) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL4844448 | 0.87 | HTT (0.58) | ALDH1A1SMN1; SMN2HTTHPGDNPC1 | |
| SCHEMBL28007665 | 0.86 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL28882986 | 0.85 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2HTTHPGDKMT2A | |
| SCHEMBL9144175 | 0.85 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL20875889 | 0.85 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL10255967 | 0.85 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTHPGDTSHR | |
| SCHEMBL7204285 | 0.85 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HTTHPGDLMNA | |
| SCHEMBL14966487 | 0.84 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2HTTLMNANPC1 | |
| SCHEMBL30633831 | 0.84 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2HTTTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447733-B | 1-benzyl-2-pyrrolinone-4-amides compound and preparation method and application | 中国药科大学 | 2016-08-17 | — | — | CN | claimed |
| CN-104447733-A | 1-benzyl-2-pyrroline ketone-4-amide compounds and preparing method and application thereof | UNIV CHINA PHARMA | 2015-03-25 | — | — | CN | claimed |
| CN-115197115-A | Preparation method and application of chiral 5-oxopyrrolidine-3-formic acid | 成都金博汇康医药科技有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-104447733-B | 1-benzyl-2-pyrrolinone-4-amides compound and preparation method and application | 中国药科大学 | 2016-08-17 | — | — | CN | disclosed |
| CN-104447733-B | 1-benzyl-2-pyrrolinone-4-amides compound and preparation method and application | 中国药科大学 | 2016-08-17 | — | — | CN | disclosed |
| CN-104447733-A | 1-benzyl-2-pyrroline ketone-4-amide compounds and preparing method and application thereof | UNIV CHINA PHARMA | 2015-03-25 | — | — | CN | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-6166015-A | Pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0526342-B1 | Isoquinolin-5yl-sulphonamides, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-12-04 | — | — | EP | disclosed |
| EP-0526342-A1 | Isoquinolin-5yl-sulphonamides, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | ALDH1A1 2549/4885SMN1; SMN2 3554/4885HTT 3482/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | ALDH1A1 1342/4885SMN1; SMN2 1401/4885HTT 1719/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | ALDH1A1 2482/4885SMN1; SMN2 3041/4885HTT 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.